ASHP Seeks Clarification on Federal Guidance for Pharmacies on Reproductive Health

Published: July 14, 2022

ASHP today warned the White House that language included in the Biden administration's new guidance for pharmacies on access to comprehensive reproductive healthcare services may have the unintended effect of limiting pharmacists' authority and clinical decision-making, to the detriment of patients.

In a letter to President Biden, ASHP Chief Executive Officer Paul W. Abramowitz noted that the guidance prohibits discrimination involving the making of determinations about the suitability of prescribed medications or advising patients how to take medications. The letter asks the Department of Health and Human Services to clarify that the guidance is not intended to limit the pharmacist–patient relationship or pharmacists' clinical decision-making. The letter also seeks guidance on the interaction of state and federal laws regarding reproductive health.

Posted July 14, 2022

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information